



The MIGHTY MEDIC Global Scientific Society

12th Lipid Club and Therapeutic Apheresis 2017

> May 3-4, 2017 Rome Istituto Salesiano Sacro Cuore





General Assembly of Members

MIGHTY MEDIC ENGLISH WEBSITE

MIGHTY MEDIC

Multidisciplinary International Group for Hemapheresis TherapY and MEtabolic DIsturbances Contrast

COORDINATION:

Prof. Claudia Stefanutti

Head of Extracorporeal Therapeutic Techniques Unit Dept. of Molecular Medicine

Dept. of Immunohematology and Transfusion Medicine

University 'La Sapienza'

'Umberto I' Hospital

Rome (Italy)



ITALIAN SECTION



EUROPEAN SECTION

Scientific committee

Dr. Mariko HARADA-SHIBA M.D., Ph.D.

Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute

Prof. Dr. Med. ULRICH JULIUS

Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden

Prof. CLAUDIA STEFANUTTI, M.D., Ph.D.

'Sapienza' University of Rome 'Umberto I' Hospital

www.mightymedic.org

Expanding the members of the Scientific Committee

Proposed:

- 1_ Prof. Gerald Watts
- 2_ Prof. Patrick Moriarty

Expanding the Board of Trustees – MIGHTY MEDIC Org

- 1_Prof. Kurt Widhalm
- 2_Prof. Albert Wiegman
- 2_Prof. Bernd Hohenstein
- 3_ Prof. Livia Pisciotta
- **4_Prof. Ornella Guardamagna**
- 5_Dr. Jeanine Roeters Van Lannep
- **6**_ Dr. Handrean Soran



New applications for the Membership (MIGHTY MEDIC Org)

Dr. Maria Grazia ZENTI

Dr. Maria GOZZER


Dr. Mahnaz SHAFII

Dr. Nicoletta DE LUCA

Dr. Daniele BERRETTI

Dr. Federica VACONDIO





New applications for the Membership (MIGHTY MEDIC Org)

Prof. Sun YUHUA, Ph.D, MD,

Cardiovascular Institute & Fu Wai Heart Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Center for Cardiovascular Disease Control and Research, Beijing, China

Jining Cardiovascular & Cerebral Hospital, Hemodilution Institute of Jining Medical College, Jining City, Shandong Province, China.

Prof Michal VRABLIK, MD, PhD,

3rd Dept. of Medicine, 1st School of Medicine, 1st Faculty of Medicine, Charles University in Prague, the Czech Republic



Do we have to change our name?

Current

http://www.mightymedic.org/en/

Multidisciplinary International Group for Hemapheresis Therapy and MEtabolic Disturbances Contrast

Proposed

http://www.mightymedic.org/en/

Multidisciplinary International Group for Hemapheresis Therapy and MEtabolic

Disorders Control?

The President's suggestion

Honorary Members

Mrs Jules PAYNE Heart UK – The Cholesterol Charity

Mrs Gabriele Hanauer-Mader – FHchol Austria

Dr Francesco Fuggetta O.M.A.R. Italia



Towards an international consensus – integrating lipoprotein apheresis and new lipid-lowering drugs

Claudia Stefanutti1*, Ulrich Julius, Gerald F Watts, Mariko Harada-Shiba, Maria Cossu, Volker J Schettler, Giustina De Silvestro, Handrean Soran, Jeanine Roeters Van Lennep, Livia Pisciotta1, Hans U Klör, Kurt Widhalm, Patrick M Moriarty and the MIGHTY MEDIC Multinational Society



Accepted April 2017, in press



BACKGROUND

Although many important advances are being made in the field of LLT, many dyslipidemic patients still do not attain sufficient lipid lowering, and, as a result, they remain at high CVD risk. Novel lipid-lowering agents may be promising to further reduce CVD risk if conventional therapies do not yield adequate results, with or without LA

AIM

 Mighty Medic would like to contribute to field-specific knowledge by publishing regularly updated concrete proposals for an international consensus on LA, covering known and new indications, how to deal with special patient groups, and what can be achieved with combination therapy with novel drugs

MORE STUDIES

However, to date the only published evidence on combination therapy of LA with novel therapeutic options is on lomitapide, alirocumab and CER-001. Thus, more studies on combining LA with inhibitors of PCSK9 or apoB synthesis, and other novel lipid-lowering strategies in development, are highly warranted

HIGHLIGHTS

 Our position paper is the first comprehensive attempt to provide recommendations to integrate novel lipid-lowering therapies with LA in severe, chronic dyslipidaemias

PROJECTS TO GO

Mighty Medic would like to set up the proposed international registry on LA, network with sister societies (International Society for Apheresis [ISFA; E-ISFA], American Society for Apheresis [ASFA], World Apheresis Association [WAA]), and other scientific societies focused on these arguments such as the International Atherosclerosis Society (IAS), National Lipid Association (NLA) Lipid-Liga - Germany, Italian Society of Nephrology (SIN), Italian Society of Hemapheresis (SidEM), and facilitate multicentre scientific collaborations on genetic, mechanistic and pooled case studies.

MIGHTY MEDIC - National research and scientific activities

Multicentre study on predictive profile of cardiovascular risk in patients with HyperLp(a)lipidaemia - isolated and combined forms - by means of descriptive analysis of genetic polymorphisms, isoforms of Lp(a), and cholesterol loading capacity (CLC)





ROMA

GENOVA

PARMA

VERONA

REGGIO EMILIA

SASSARI

EDUCATIONAL ACTIVITY

Ongoing

The MIGHTY MEDIC Org FALL SCHOOL of CLINICAL LIPIDOLOGY (Italy)

Future project

The MULTINATIONAL MIGHTY MEDIC Org SCHOOL of CLINICAL LIPIDOLOGY

